Immunome, Inc. announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company?s proprietary oncology pipeline.

Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer. Dr. Lechleider began his biotech career at MedImmune (an Astra Zeneca company) and went on to positions of increasing responsibility at Human Genome Sciences and Macrogenics before heading development at Seagen. Prior to his career in biotech, Dr. Lechleider held academic positions where he studied basic cellular and molecular biology.

Dr. Lechleider earned his A.B. from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago before receiving his clinical residency in internal medicine at Beth Israel-Deaconess Medical Center in Boston, and later in medical oncology at the National Cancer Institute (NCI) in Bethesda.